Last update: Jan. 15, 2020
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Bactericidal disinfectant which is effective against Gram-positive and Gram-Negative bacteria, fungi and virus.
Used as a disinfectant for medical instruments (endoscopes, dental material, etc.) and in endodontic treatments (INSS 2008, Rusmah 1993).
It is also used to treat warts and hyperhidrosis (Dall'oglio 2012).
Since the last update we have not found published data on its excretion in breastmilk.
In topical treatment for warts, the small dose and minimal plasma absorption makes it unlikely it will transfer into breastmilk in significant quantities. Do not apply on the breast so as to avoid the infant ingesting it.
Similarly, there is minimal absorption via endodontic treatments (Rusmah 1993).
Acute and prolonged inhalation of glutaral in concentrations over the permitted level may cause irritation of the mucous membranes of the respiratory tract, occupational asthma and nervousness (Copeland 2015, Rosenman 2015, Nayebzadeh 2007, Takigawa 2006).
Direct skin contact causes irritation and contact dermatitis (ILO 2018).
It is necessary to ensure adequate ventilation in workplaces in order to maintain glutaral levels below 0.05 ppm, automatic disinfection units, suitable protection material and adequate information for workers (ILO 2018, INSHT 2017, INSS 2008, Nayebzadeh 2007, d'Angelo 2006, Jordan 1995).
Glutaral does not have carcinogenic or mutagenic effects (Takigawa 2006).
The small amount that reaches the plasma via inhalation due to its irritant capacity, is quickly metabolized to carbon dioxide, CO2, which is eliminated by the kidneys or respiratory tract (Rusmah 1993).
With regard to occupational risks for breastfeeding mothers (INSHT 2017, EC Regulation 2008), there are only two risk phrases (old R-phrases, currently H-phrases for hazard) or precaution phrases (P-phrases) that should appear on the product’s safety data sheet:
- H362 (R64): "May cause harm to breast fed children"
- P263: "Avoid contact during pregnancy/while nursing”
Three other phrases that should be considered during breastfeeding are related to the carcinogenic, mutagenic or cumulative strength of a product:
H351 (ant. R40): “Possible carcinogenic effect"
- H351 (ant. R40): "Possible carcinogenic effects"
- H371 (ant. R68): "Possible risk of irreversible effects”
- H373 (ant. R33):" Danger of cumulative effects”
Based on the absence of these phrases in the safety data sheet of glutaral (ILO 2018) and in government lists (INSHT 2017, EC Regulation 2008), it would not be necessary to remove a breastfeeding mother from her job, and it would be enough for the company to meet legal requirements regarding the maximum levels of environmental exposure and for the employee to follow recommended rules of caution (gloves, hand and face washing, change of clothes, etc.)
List of WHO essential medicines: compatible with breastfeeding (WHO / UNICEF 2002).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM